OBJECTIVES: This review investigates trends in NICE single technology appraisals (STAs) in haematology since the introduction of the new Cancer Drugs Fund (CDF) in July 2016, to better understand decision making. METHODS: A targeted review was conducted of NICE haematology STAs published on the NICE website. All STAs with a Technology Appraisal Guidance (TAG) published since the introduction of the new CDF in July 2016 to June 2018 were included. RESULTS: A total of 24 STAs were identified: 11 were recommended for baseline commissioning, 6 were recommended for the CDF, 1 was not recommended and 6 were terminated. All 6 of the CDF recommended STAs were drugs with multiple indications with Managed Access Agreements (MAAs) in place. The average time from submission to TAG was 9.2 (3-21) months for therapies recommended for baseline commissioning versus 17.8 (13-26) months for therapies recommended for the CDF. Several uncertainties were identified with CDF recommended therapies: phase II trial data (4), immature survival data (5) and lack of appropriate comparator (1). CONCLUSIONS: A quarter of haematology therapies were recommended for interim funding on the new CDF. CDF recommended haematology STAs are characterised by longer average duration, restricted populations and MAAs. From the initial two years of the new CDF, predictors for a CDF recommendation include non-comparative evidence, immature survival data, and comparators not relevant to UK clinical practice; however, longer term evidence is needed to confirm these trends. Further research should include whether data collection through the CDF can sufficiently reduce uncertainty for decision making purposes, and allow new therapies to be granted a final positive recommendation through NICE.